A5103325730- Gastrointestinal Tumor Research and Treatment
- Gastrointestinal disorders and treatments
- Gastric Cancer Management and Outcomes
- Sarcoma Diagnosis and Treatment
- Vascular Malformations and Hemangiomas
- Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Gastroesophageal reflux and treatments
- Platelet Disorders and Treatments
- Esophageal and GI Pathology
- Cancer Immunotherapy and Biomarkers
- Chronic Lymphocytic Leukemia Research
- Ferroptosis and cancer prognosis
- Metastasis and carcinoma case studies
- Dysphagia Assessment and Management
- Cancer-related molecular mechanisms research
The Affiliated Yongchuan Hospital of Chongqing Medical University
2018-2025
Chongqing Medical University
2018-2025
11518 Background: NB003 is a potent and selective small-molecule tyrosine kinase inhibitor of KIT/PDGFRα. It was designed to inhibit broad spectrum primary acquired imatinib-resistant mutations in Methods: This first-in-human phase 1 study patients (pts) with advanced GIST who progressed on or intolerant imatinib other SoCs. Pts received oral twice daily (BID). An accelerated titration followed by Bayesian optimal interval (BOIN) design used. After the MTD MAD determined, putative RP2D(s)...
BACKGROUND For patients with advanced gastrointestinal stromal tumors (GISTs) carrying the c-kit exon 11 mutation, imatinib (IM) at a standard dosage of 400 mg per day is preferred first-line treatment. In cases where treatment IM fails, there an urgent need for more precise assessment method to determine whether switch therapies or escalate dosage. This approach will enhance clinical decision-making and optimize patient outcomes. AIM To investigate plasma concentration’s role in second-line...
Abstract Purpose: This is a phase II multicenter, single-arm, open-label study assessing the efficacy, safety, and pharmacokinetics (PK) of ripretinib in Chinese patients with advanced gastrointestinal stromal tumor (GIST) as fourth- or later-line therapy. It was designed to show consistency III INVICTUS study. Patients Methods: disease progression on (or intolerance to) prior imatinib, sunitinib, at least one other drug were recruited receive 150 mg once daily continuously 28-day cycles....
Imatinib plasma trough levels (IM Cmin) have been reported to a considerable clinical impact in patients with gastrointestinal stromal tumors (GISTs). We therefore investigated the factors affecting IM concentration Chinese GIST patients.IM Cmin 190 who were taking measured.In treated 300 mg/day (n = 16), 400 168), and > (500: n 1, 600: 5), was 1,564.54 ± 596.15, 1,521.26 610.33, 2,540.31 1,298.14 ng/mL, respectively. Of 168 mg/day, significantly lower males (1,353.94 492.89 ng/mL) than...
Background: Tyrosine kinase inhibitors (TKIs) have shown great efficacy in the treatment of advanced gastrointestinal stromal tumors (GISTs), significantly prolonging survival patients. In era imatinib, a few studies reported some prognostic factors for patients with GISTs, such as age, sex, performance status, diameter largest lesions, KIT exon mutations, and hematological examination results. However, advent more TKIs, GISTs not been fully understood multiple TKIs. this study, we aimed to...
Objectives: There is disagreement over the prognostic value of multidisciplinary team (MDT) discussion for advanced gastrointestinal stromal tumors (GISTs). This study examined how an MDT affected patients with GISTs in terms their overall survival (OS) and whether it may enhance performance status (PS). Methods: A retrospective data analysis was conducted on between 2000 2022. Depending they had received intervention, were split into two groups. The OS groups compared using Kaplan–Meier...
Abstract Purpose: The efficacy of the selective KIT/PDGFRA inhibitor avapritinib (300 mg once daily) was explored in patients with non–PDGFRA-mutant gastrointestinal stromal tumors (GISTs) from phase I NAVIGATOR and I/II CS3007–001 trials. Patients Methods: Adults unresectable/metastatic, KIT-only-mutant GISTs progression following ≥1 tyrosine kinase inhibitors (TKIs) were included this post hoc analysis. Baseline mutational status identified tumor plasma. Primary endpoints objective...
Gender is associated with medication adherence for imatinib, but whether it related to the prognosis of primary localized gastrointestinal stromal tumors (GISTs) unclear. The goal this study was clarify relationship between gender and in GIST patients, differences considered.The data 320 patients were retrospectively collected from First Affiliated Hospital Chongqing Medical University. Survival analysis performed using Kaplan-Meier method (Log rank test) risk factors recurrence determined...
Endoscopic submucosal dissection (ESD), an emerging technique originated from Japan, has been introduced into China in recent years. The aim of this study was to evaluate the efficacy and safety ESD treatment gastrointestinal (GI) neoplasms.Early GI neoplasms (n=41) 40 patients local Eastern were treated with at Zhejiang Provincial People's Hospital followed-up January 2009 December 2011. Postoperative pathology, complications therapeutic outcomes retrospectively analyzed.Mean size resected...
<div>AbstractPurpose:<p>The efficacy of the selective KIT/PDGFRA inhibitor avapritinib (300 mg once daily) was explored in patients with non–<i>PDGFRA</i>-mutant gastrointestinal stromal tumors (GISTs) from phase I NAVIGATOR and I/II CS3007–001 trials.</p>Patients Methods:<p>Adults unresectable/metastatic, <i>KIT</i>-only-mutant GISTs progression following ≥1 tyrosine kinase inhibitors (TKIs) were included this <i>post hoc</i>...
<div>AbstractPurpose:<p>The efficacy of the selective KIT/PDGFRA inhibitor avapritinib (300 mg once daily) was explored in patients with non–<i>PDGFRA</i>-mutant gastrointestinal stromal tumors (GISTs) from phase I NAVIGATOR and I/II CS3007–001 trials.</p>Patients Methods:<p>Adults unresectable/metastatic, <i>KIT</i>-only-mutant GISTs progression following ≥1 tyrosine kinase inhibitors (TKIs) were included this <i>post hoc</i>...
<p>Supplementary Figure S1. Examples of remarkable tumor regression in patients with KIT-only-mutant GIST during treatment avapritinib 300 mg QD.</p>
<p>Supplementary Figure S1. Examples of remarkable tumor regression in patients with KIT-only-mutant GIST during treatment avapritinib 300 mg QD.</p>
Chemokines have been reported to be involved in tumorigenesis and progression can also modulate the tumor microenvironment. However, it is still unclear whether chemokine-related long noncoding RNAs (lncRNAs) affect prognosis of colon adenocarcinoma (COAD). We summarized genes downloaded RNA-seq clinical data from The Cancer Genome Atlas (TCGA) database. A total 52 prognostic lncRNAs were screened by univariate Cox regression analysis; patients grouped according cluster analysis results....
Abstract Objective: To evaluate the pharmacokinetic (PK) parameters of ripretinib and its active metabolite in Chinese patients with gastrointestinal stromal tumor (GIST), to examine potential ethnic differences drug exposure between global patient populations using both population non-compartmental PK methods. Methods: An ongoing clinical phase 2 bridging study China had enrolled 29 advanced GIST who underwent intensive or sparse sampling at a dose 150 mg QD. The plasma samples were...
Supplementary Figure from Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study
Supplementary Data from Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study
<div>AbstractPurpose:<p>This is a phase II multicenter, single-arm, open-label study assessing the efficacy, safety, and pharmacokinetics (PK) of ripretinib in Chinese patients with advanced gastrointestinal stromal tumor (GIST) as fourth- or later-line therapy. It was designed to show consistency III INVICTUS study.</p>Patients Methods:<p>Patients disease progression on (or intolerance to) prior imatinib, sunitinib, at least one other drug were recruited receive 150...
Supplementary Figure from Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study
Supplementary Figure from Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study
Supplementary Figure from Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study